Wegovy, Ozempic added to list of drugs where the federal government will try winning discounts from manufacturers.

UnitedHealth Group (NYSE:UNH), a leading diversified healthcare company with a substantial market capitalization of $469.7 ...

Insurer-pharmacy benefit manager (PBM) firms control most of the Medicare Part D market, steering patients to their ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden adds Ozempic to list for Medicare price negotiationIn one of its last actions, the Biden ...

The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but ...

UnitedHealth Q4 earnings beat EPS estimates at $6.81 but missed revenue projections. Analysts highlight growth potential in ...

Healthcare fraud investigations accounted for more than half of the Department of Justice's settlements and judgments in 2024 ...

As government scrutiny and enforcement targeting the Medicare Advantage (Medicare Part C) program continued in 2024, the ...

KeyBanc Capital Markets reiterated its Overweight rating on UnitedHealth Group shares (NYSE:UNH), maintaining a price target ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

Analyst Joanna Gajuk of Bank of America Securities maintained a Buy rating on UnitedHealth (UNH – Research Report), reducing the price target ...